ORIGINAL ARTICLE
The significance of StAR-related lipid transfer protein-3 expression in breast cancer
1
Departament of Medical Laboratory Sciences, Faculty of Science, Al-Balqa Applied University, Al-Salt, Jordan
2
Department of Basic Medical Sciences, Faculty of Medicine, Al-Balqa Applied University, Al-Salt, Jordan
3
Department of Pathology and Forensic Medicine, Faculty of Medicine, Al-Balqa Applied University, Al-Salt, Jordan
Submission date: 2021-12-12
Final revision date: 2022-09-15
Acceptance date: 2022-10-15
Publication date: 2023-01-10
Pol J Pathol 2022;73(3):215-222
KEYWORDS
TOPICS
ABSTRACT
StAR-related lipid transfer domain containing proteins (STARD3) are a group of proteins that contain a steroidogenic acute regulatory protein-related lipid transfer domain. Breast cancer (BC) has been linked to the STARD3 gene. In this study, we sought to confirm the relationship of STARD3 protein expression with clinicopathological characteristics and BC molecular subtypes.
Using tissue microarray, we examined the STARD3 protein expression in 200 BC tissues and 20 normal breast tissues.
Higher protein expression of STARD3 was found in tumor tissues than normal tissues. One hundred and fifty-two (69.1%) of the 200 cases tested positive for STARD3 (high H-score), while seventy (30.9%) had a low STARD3 H-score. When STARD3 is present, its expression ranges from mild to strong. STARD3 H-score was strongly linked to human epidermal growth factor receptor 2 (HER2)-positive (p < 0.001) and estrogen receptor (ER)-positive (p < 0.009) patients, but not to triple-negative BC patients.
STARD3 high H-score was associated with histological grade and tumor size. No significant associations were found with stage of the disease, pathological stage or node status. Our research revealed that STARD3 levels were higher in tissues from malignant BC, and it was associated with HER2 and ER, suggesting that it might be utilized as a marker for BC.
Using tissue microarray, we examined the STARD3 protein expression in 200 BC tissues and 20 normal breast tissues.
Higher protein expression of STARD3 was found in tumor tissues than normal tissues. One hundred and fifty-two (69.1%) of the 200 cases tested positive for STARD3 (high H-score), while seventy (30.9%) had a low STARD3 H-score. When STARD3 is present, its expression ranges from mild to strong. STARD3 H-score was strongly linked to human epidermal growth factor receptor 2 (HER2)-positive (p < 0.001) and estrogen receptor (ER)-positive (p < 0.009) patients, but not to triple-negative BC patients.
STARD3 high H-score was associated with histological grade and tumor size. No significant associations were found with stage of the disease, pathological stage or node status. Our research revealed that STARD3 levels were higher in tissues from malignant BC, and it was associated with HER2 and ER, suggesting that it might be utilized as a marker for BC.
REFERENCES (25)
1.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249.
2.
Masuda S. Breast cancer pathology: the impact of molecular taxonomy on morphological taxonomy. Pathol Int 2012; 62: 295-302.
3.
Kakudji BK, Mwila PK, Burger JR, du Plessis JM, Naidu K. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study. Pan Afr Med J 2021; 38: 85.
4.
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
5.
Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15: 429-440.
6.
O’Brien NA, Browne BC, Chow L, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010; 9: 1489-1502.
7.
Alpy F, Boulay A, Moog-Lutz C, et al. Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors. Oncogene 2003; 22: 3770-3780.
8.
Di Mattia T, Wilhelm LP, Ikhlef S, et al. Identification of MOSPD2, a novel scaffold for endoplasmic reticulum membrane contact sites. EMBO Rep 2018; 19: e45453.
9.
Alpy F, Rousseau A, Schwab Y, et al. STARD3 or STARD3NL and VAP form a novel molecular tether between late endosomes and the ER. J Cell Sci 2013; 126: 5500-5512.
10.
Almarhoun M, Biswas L, Alhasani RH, et al. Overexpression of STARD3 attenuates oxidized LDL-induced oxidative stress and inflammation in retinal pigment epithelial cells. Biochim Biophys Acta Mol Cell Biol Lipids 2021; 1866: 158927.
11.
Charman M, Kennedy BE, Osborne N, Karten B. MLN64 mediates egress of cholesterol from endosomes to mitochondria in the absence of functional Niemann-Pick Type C1 protein. J Lipid Res 2010; 51: 1023-1034.
12.
Elustondo P, Martin LA, Karten B. Mitochondrial cholesterol import. Biochim Biophys Acta Mol Cell Biol Lipids 2017; 1862: 90-101.
13.
Vassilev B, Sihto H, Li S, et al. Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers. Am J Pathol 2015; 185: 987-1000.
14.
Moog-Lutz C, Tomasetto C, Regnier CH, et al. MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over-expressed in human breast carcinomas. Int J Cancer 1997; 71: 183-191.
15.
Sahlberg KK, Hongisto V, Edgren H, et al. The HER2 amplicon includes several genes required for the growth and survival of HER2-positive breast cancer cells. Mol Oncol 2013; 7: 392-401.
16.
Fararjeh A F S AKA, Kaddumi E, Obeidat M, AL-Fawares O. Differential expression and prognostic significance of STARD3 gene in breast carcinoma. Int J Cancer 2021; 10: 34-44.
17.
Fararjeh AS, Chen LC, Ho YS, et al. Proteasome 26S Subunit, non-ATPase 3 (PSMD3) regulates breast cancer by stabilizing HER2 from degradation. Cancers (Basel) 2019; 11: 527.
18.
Kotoula V, Bobos M, Alexopoulou Z, et al. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17. PLoS One 2014; 9: e103707.
19.
Qiu Y, Zhang ZY, Du WD, et al. Association analysis of ERBB2 amplicon genetic polymorphisms and STARD3 expression with risk of gastric cancer in the Chinese population. Gene 2014; 535: 225-232.
20.
Stigliano A, Gandini O, Cerquetti L, et al. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 2007; 194: 55-61.
21.
Fararjeh AFS, Al Khader A, Kaddumi E, Obeidat M, Al-Fawares O. Differential expression and prognostic significance of STARD3 gene in breast carcinoma. Int J Mol Cell Med 2021; 10: 34-41.
22.
Yun SM, Yoon K, Lee S, et al. PPP1R1B-STARD3 chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K/AKT signaling. Oncogene 2014; 33: 5341-5347.
23.
Dressman MA, Baras A, Malinowski R, et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003; 63: 2194-2199.
24.
Cai W, Ye L, Sun J, Mansel RE, Jiang WG. Expression of MLN64 influences cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase. Int J Mol Med 2010; 25: 573-580.
25.
Zhou X, Gao H, Guo Y, Chen Y, Ruan XZ. Knocking down Stard3 decreases adipogenesis with decreased mitochondrial ROS in 3T3-L1 cells. Biochem Biophys Res Commun 2018; 504: 387-392.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
